|Bid||74.00 x 1400|
|Ask||82.75 x 1000|
|Day's Range||75.32 - 76.80|
|52 Week Range||61.05 - 82.25|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||25.63|
|Forward Dividend & Yield||0.76 (0.93%)|
|1y Target Est||N/A|
According to the GuruFocus All-in-One Screener, the following companies are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 5 Warning Signs with CHA. Shares of China Telecom Corp. Ltd. (CHA) are trading around $52 per share.
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could Apple and Qualcomm’s Settlement Mean Upside for Point72?Steve Cohen’s Point72 Management Steve Cohen is a very high-profile investor whose SAC capital returned 30% annually for more than 20 years. In 2012, the firm was found guilty of
Baxter International Inc. (NYSE:BAX) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case of BAX, it...
Good news continues to benefit Baxter International (NYSE:BAX) stock. The Deerfield, Illinois-based medical equipment company received Food and Drug Administration (FDA) approval for its latest version of Floseal. Floseal already led the industry among blood-clotting solutions, so how it affects BAX stock remains unclear.Source: Shutterstock However, with a demographic trend that continues to favor all things healthcare, it serves as yet another reason to buy Baxter International stock. Baxter Improves FlosealBaxter just received approval from the FDA for its next generation of its Floseal Hemostatic Matrix. The company designed Floseal to stop bleeding during surgeries when more conventional procedures fail. The company reduced both the components and the steps to prepare by 20% in this latest version.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Floseal has become a success for Baxter. Despite its higher price, it comes out ahead of Surgiflo, the competing product produced by Johnson & Johnson's (NYSE:JNJ) Ethicon. The Bulls and BAX stockInterestingly, despite the compelling benefits Floseal appears to offer, it may not affect BAX significantly. The Advanced Surgery division which produces Floseal remains one of the company's smaller divisions. The Renal Care, Medication Delivery, Pharmaceuticals, and Clinical Nutrition divisions all generate more revenue for the company.Moreover, the slow, steady increases in BAX began 3.5 years ago. It traded at just under $33 per share in the fall of 2015. Today, it has risen to over $79 per share. This places it just shy of its all-time high of $82.25 per share where it peaked last month.BAX also continues a pace of steady profit growth, which should rise to double-digit levels next year. Moreover, it trades at a forward price-to-earnings (PE) ratio of 21.3. This places its multiple close to long-term averages. It also makes it a cheaper stock than another peer, Abbott Laboratories (NYSE:ABT) Medicare Is Key for BAXIn most cases, I would call a stock with such metrics a hold. However, demographics provide a catalyst that will help BAX for now even if it failed to improve its products. The baby boom generation continues to age into Medicare at a rapid pace. A similar trend has appeared in other countries. This population's need for more medical care almost guarantees an increase in profits for BAX over the next few years.The peak of the baby boom occurred in 1957. Hence, age-ins to Medicare will peak 65 years after that year, meaning 2022. For this reason, I would expect at least three more years of a rising BAX.This trend has already helped take the financials higher. Both revenue and dividends for BAX have risen every year since 2016. The 0.95% yield on the dividend probably will not motivate investors to buy. However, the annual increases for the payout likely reflect the bullish sentiment. The Bottom Line on BAX StockAlthough a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX. As the leading product for blood clotting, the enhanced version of Floseal should help ensure that Baxter maintains its lead over Ethicon's Surgiflo.Still, the millions of baby boomers entering Medicare will more than likely remain the number one reason to buy BAX stock. With a greater need for care and the backing behind Medicare to pay, Baxter will benefit from this growing book of business for years to come.The market will always welcome product improvements. Despite this benefit, the growth in BAX will remain tied primarily to Medicare age-ins for the foreseeable future.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post The Future Keeps Looking Better and Better for BAX Stock appeared first on InvestorPlace.
At the end of February 2019, Daniel Loeb's Third Point published its Q4 2018 Investor Letter, in which it shared its views on a few companies from its 13F portfolio. You can track a copy of the letter - here. Among the stocks it discussed was Baxter International Inc. (NYSE:BAX), the fund's largest position. The […]
Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding BAX are favorable, with net inflows of $11.54 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BAX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Today we'll look at Baxter International Inc. (NYSE:BAX) and reflect on its potential as an investment. To be precise, we'll...
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of December 31. The results of that effort will be put on display in this article, as […]
The launch of Clinolipid will be a crucial step toward Baxter's (BAX) goal of strengthening its lipid portfolio and offering enhanced health care to malnourished patients.
Baxter International Inc. (BAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Investment company Morgan Stanley Institutional Global Franchise Fund buys Baxter International Inc, Heineken NV during the 3-months ended 2018Q4, according to the most recent filings of the investment ...
Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Every investor in Baxter International Inc. (NYSE:BAX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...